Medpace Holdings Inc 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file TABLE OF CONTENTS Item NumberPagePART I — FINANCIAL INFORMATION3Item 1.Financial Statements (unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20253Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20254Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2026and 20255Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2026 and20256Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20257Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24 MEDPACE HOLDINGS, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)March31, 2026 (1) Basis of Presentation Description of Business Medpace Holdings, Inc. (together with its subsidiaries, “Medpace” or the “Company”), a Delaware corporation, is a global provider ofclinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology,and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus onfull service Phase I-IV clinical development services and include development plan design, project management, regulatory affairs, The Company’s operations are principally based in North America, Europe, and Asia. Unaudited Interim Financial Information The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S.generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustmentsof a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normallyincluded in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, hasbeen omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires Share Repurchases In 2022, the Company’s Board of Directors (the "Board") approved a share repurchase program which has been amended several timesto increase the aggregate amount of the share repurchase authorization. The Company did not execute any share repurchases during thethree months ended March31, 2026. During the three months ended March31, 2025, the Company repurchased 1,193,011 shares for Repurchases under the share repurchase program are executed in the open market or negotiated transactions under trading plans put inplace pursuant to Rule 10b5-1. The Company constructively retired the repurchased shares associated with these approved sharerepurchases, except for a small portion which were retained as Treasury Shares on the condensed consolidated statements of Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense DisaggregationDisclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures by providing more detailedinformation about the types of expenses in commonly presented expense captions. The guidance is effective for annual reportingperiods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early In September 2025, the FASB issued ASU 2025-06, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40):Targeted Improvements to the Accounting for Internal-Use Software” to modernize the accounting for software development costs andspecify disclosure requirements. The guidance is effective for annual periods beginning after December 15, 2027, and interim of the beginning of an annual reporting period. The Company is currently evaluating the effect this standard will have on its In December 2025, the FASB issued ASU 2025-10, "Government Grants (Topic 832): Accounting for Government Grants Received byBusiness Entities" which establishes authoritative US GAAP guidance for accounting for grants received for consistency in applyingthe accounting rules across business entities. The guidance is effective for annual reporting periods beginning after December 15,2028, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently (2) Net Income Per Share Basic and diluted earnings or loss per share (“EPS”) are computed us